ibudilast has been researched along with Emesis in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ibudilast was generally well tolerated." | 2.73 | Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses. ( Chang, E; Davidson, JB; Gibbons, JA; Gross, MI; He, L; Johnson, KW; Jones, D; Rolan, P; Sanftner, LM, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Peng, T | 1 |
| Qi, B | 1 |
| He, J | 1 |
| Ke, H | 1 |
| Shi, J | 1 |
| Rolan, P | 1 |
| Gibbons, JA | 1 |
| He, L | 1 |
| Chang, E | 1 |
| Jones, D | 1 |
| Gross, MI | 1 |
| Davidson, JB | 1 |
| Sanftner, LM | 1 |
| Johnson, KW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Regeneration in Cervical Degenerative Myelopathy - a Multi-centre, Double-blind, Randomised, Placebo Controlled Trial Assessing the Efficacy of Ibudilast as an Adjuvant Treatment to Decompressive Surgery for Degenerative Cervical Myelopathy[NCT04631471] | Phase 3 | 400 participants (Anticipated) | Interventional | 2021-12-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ibudilast and Emesis
| Article | Year |
|---|---|
Advances in the Development of Phosphodiesterase-4 Inhibitors.
Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Development; Drug Discovery; Humans; Mol | 2020 |
1 trial available for ibudilast and Emesis
| Article | Year |
|---|---|
Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses.
Topics: Adolescent; Adult; Aged; Chronic Disease; Diabetic Neuropathies; Dose-Response Relationship, Drug; D | 2008 |